Can two old drugs together save young livers?
NCT ID NCT06091345
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving both midodrine (a blood-pressure drug) and albumin (a protein infusion) to children with cirrhosis and fluid buildup (ascites) could prevent serious complications like kidney injury, low sodium, and confusion. Sixty-one children were split into two groups: one got midodrine plus albumin, the other got midodrine alone. The goal was to see if the combo worked better than midodrine alone at reducing these life-threatening problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
midodrine and albumin
What this could lead to
If successful, this combination could help prevent serious complications like kidney injury and improve survival in children with advanced liver disease.
What could go wrong
This is a small, single-center trial with only 61 children. The results may not apply to all patients, and the combination may not provide a clear benefit over standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Liver & Biliary Sciences (ILBS)
New Delhi, National Capital Territory of Delhi, 110 070, India